Article
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
Cancer prevention research (Philadelphia, Pa.) - 1 May 2010
Lipkin Steven M, Chao Elizabeth C, Moreno Victor, Rozek Laura S, Rennert Hedy, Pinchev Mila, Dizon Diana, Rennert Gad, Kopelovich Levy, Gruber Stephen B
Abstract excerpt
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), the rate-limiting enzyme in cholesterol synthesis, modifies the effect of statins on serum cholesterol levels. Long-term use of statins is associated with a reduced risk of colorectal cancer (CRC) in some, but not all, studies. We genotyped variants in 40 candidate genes important for cholesterol synthesis and metabolism in a population-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.